Select a medication above to begin.
Hympavzi (marstacimab-hncq)
marstacimab
Adult Dosing .
Dosage forms: INJ (pen): 150 mg per mL; INJ (pre-filled syringe): 150 mg per mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = marstacimab-hncq
routine bleeding prophylaxis, hemophilia A or B
- [150 mg SC qwk]
- Start: 300 mg SC x1; Info: D/C prophylactic factor VIII or factor IX concentrates before tx start; consider incr. dose to 300 mg SC qwk if wt >50 kg and inadequate bleeding control; may use lowest effective dose of factor VIII or factor IX concentrates for breakthrough bleeding
renal dosing
- [see below]
- eGFR >60: no adjustment; eGFR <60: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- mild impairment: no adjustment; moderate-severe impairment: not defined
Peds Dosing .
- Dosage forms: INJ (pen): 150 mg per mL; INJ (pre-filled syringe): 150 mg per mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = marstacimab-hncq
routine bleeding prophylaxis, hemophilia A or B
- [12 yo and older]
- Dose: 150 mg SC qwk; Start: 300 mg SC x1; Info: D/C prophylactic factor VIII or factor IX concentrates before tx start; consider incr. dose to 300 mg SC qwk if wt >50 kg and inadequate bleeding control; may use lowest effective dose of factor VIII or factor IX concentrates for breakthrough bleeding
renal dosing
- [see below]
- eGFR >60: no adjustment; eGFR <60: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- mild impairment: no adjustment; moderate-severe impairment: not defined
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- prophylactic clotting factor concentrate use, concurrent
- major surgery periop use
- baseline factor VIII inhibitors titer test positive
- baseline factor IX inhibitors titer test positive
- caution: pts of childbearing potential
- caution: illness, acute severe
Drug Interactions .
Overview
marstacimab
tissue factor pathway inhibitor antagonist
- thrombogenic effects
Monitor/Modify Tx
- anti-inhibitor coagulant complex
- antihemophilic factor (factor VIII)/von Willebrand factor complex
- coagulation factor IX
- coagulation factor VIIa
- coagulation factor XIII A-subunit
- prothrombin complex concentrate (human)
Adverse Reactions .
Serious Reactions
- thromboembolism
- hypersensitivity rxn
Common Reactions
- injection site rxn
- headache
- pruritus
Safety/Monitoring .
Monitoring Parameters
pregnancy test at baseline
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human or animal data available; possible risk of fetal harm based on drug's mechanism of action
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x2mo after D/C in pts of childbearing potential
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: catabolism; CYP450: unknown
Excretion: other; Half-life: 7-10 days
Subclass: Hemostasis: Anti-Tissue Factor Pathway Inhibitors (TFPIs)
Mechanism of Action
binds Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2, neutralizing TFPI activity and enhancing coagulation (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.